Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
Yudai FujiwaraKazuyuki SuzukiKenji YusaMakoto EizukaManami MiuraYuki WatanabeHiroshi TakahashiYasuhiro Takikawa
Author information
JOURNAL OPEN ACCESS

2021 Volume 60 Issue 7 Pages 1027-1033

Details
Abstract

The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE.

Content from these authors
© 2021 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top